The Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, Government of India, has awarded Panacea Biotec a contract to supply bivalent oral polio vaccine (bOPV) worth INR 127.20 Crore.

In an exchange filing, the company stated that it received the Letter of Acceptance (LOA) on October 8, 2025, and the vaccine will be supplied in several tranches over a period of 90 to 480 days from the date of issuance of LOA.  

Panacea Biotec is among India’s largest vaccine manufacturers and a key partner of the Global Polio Eradication Initiative (GPEI), supplying billions of WHO pre-qualified polio vaccine doses across more than 50 countries. The company has completed the full range of oral polio vaccines, including tOPV, mOPV1, mOPV3, and bOPV (Type 1 & Type 3).

The company is also a pioneer in combination vaccines. It developed the first fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive in 2005, now WHO pre-qualified and used in over 75 countries. In 2017, Panacea Biotec launched the world’s first fully liquid wP-IPV based Hexavalent vaccine (DTwP+HepB+Hib+IPV) EasySix, which continues to serve the Indian private market.

Other vaccines in its portfolio include Enivac-HB (Hepatitis B, pediatric & adult), Ecovac-4 (DTwP+Hep B), EasyFour (DTwP+Hib), and EasyFourPol (DTwP-Hib-IPV). Vaccines in development include recombinant chimeric Dengue tetravalent, Pneumococcal Conjugate, and several others, reflecting a strong pipeline of next-generation vaccines.

Panacea Biotec’s capabilities are supported by USFDA-approved pharmaceutical manufacturing facilities at Baddi, and WHO pre-qualified vaccine production units at Lalru and Baddi (Punjab).